Glucose Health, Inc. reported a 193% year-over-year revenue increase for GlucoDown, its blood sugar support beverage, fueled by nearly doubling retail pharmacy locations and increased consumer advertising. Sales growth in two major U.S. pharmacy chains exceeded 120% and 135% respectively for early 2026 compared to 2025. The company attributes rising demand to expanded distribution and marketing efforts, positioning GlucoDown as a complementary product to popular GLP-1 therapies for metabolic health. This momentum supports a positive growth outlook through 2026 and beyond.
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
